Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 05, 2026
Why Is BrightView Holdings (BV) Stock Down -18.9% Today?

Why Is BrightView Holdings (BV) Stock Down -18.9% Today?

Key Takeaways

  • BrightView Holdings shares plunged approximately 18.9% on Wednesday, falling from a prior close of $13.12 to around $10.64 intraday.
  • The selloff was triggered by a disappointing fiscal third-quarter 2026 earnings report released after Tuesday's close, with adjusted EPS of $0.17 missing the $0.29 consensus estimate by roughly 41%.
  • A $16 million self-insurance adjustment tied to pre-2024 claims and a $4 million fuel-cost headwind weighed heavily on profitability, masking underlying operational improvements.
  • Management lowered its adjusted free cash flow guidance for full-year 2026, and full-year EBITDA guidance came in below Wall Street expectations.
  • The stock is now trading near its 52-week low, with traders watching for any signs of stabilization or further analyst downgrades in the days ahead.

Opening Summary

BV, BrightView Holdings, Inc. — the nation's largest commercial landscaping services provider — saw its stock plummet approximately 18.9% in Wednesday's trading session. Shares fell from a prior closing price of $13.12 to roughly $10.64, pushing the company's market capitalization below the $1 billion threshold and bringing the stock dangerously close to its 52-week low of $10.81. The catalyst was a fiscal third-quarter 2026 earnings report that missed Wall Street expectations on both the top and bottom lines, compounded by a lowered free cash flow outlook and significant non-routine charges that eroded profitability.

Earnings Miss Fuels Broad Selloff

BrightView reported fiscal third-quarter adjusted earnings per share of $0.17, well short of the $0.29 consensus forecast — a miss of approximately 41%. Revenue came in at $717.6 million, missing analyst estimates of roughly $726 million and representing just 1.3% year-over-year growth. While the revenue miss was modest, the magnitude of the earnings shortfall rattled investors who had been expecting the company's peak landscaping season to deliver stronger profitability.

The quarter was marked by two significant non-routine items: a $16 million self-insurance adjustment related to pre-2024 claims and an approximate $4 million headwind from elevated fuel costs. Excluding those items, adjusted EBITDA would have been $116 million with a 16.2% margin — a far healthier picture than the reported $96 million in adjusted EBITDA and 13.3% margin. Still, investors focused on the headline miss and the broader implications for the company's turnaround narrative.

Lowered Guidance Adds to Pressure

Compounding the earnings disappointment, BrightView lowered its adjusted free cash flow guidance for the full fiscal year 2026 and issued full-year EBITDA guidance of approximately $342.5 million at the midpoint, which fell below the analyst consensus of around $369 million. While the company reaffirmed its full-year revenue guidance of $2.77 billion, the weaker profitability and cash flow outlook signaled that cost pressures and one-time charges may continue to weigh on results in the near term.

The guidance cut marked a sharp reversal from the optimism that had surrounded BrightView after its second-quarter results, when the company raised its full-year revenue outlook and pointed to a turnaround in its core land maintenance business.

Operational Progress Overshadowed

Beneath the disappointing headline numbers, BrightView's underlying business showed signs of improvement. Land maintenance revenue grew 2.3% year-over-year to $514.5 million, marking the second consecutive quarter of organic growth after an extended period of contraction. The contract book of business expanded 4% from the second quarter of 2025, representing the fifth consecutive quarter of positive net new business. Customer retention improved to 84.6%, with more than half of branches now above 85% retention.

CEO Dale Asplund has described these gains as part of the company's "One BrightView" transformation strategy, but the market's reaction suggests investors remain skeptical about whether operational improvements can translate into consistent, profitable growth — particularly as non-routine charges continue to obscure underlying progress.

Market Context and Trading Activity

The selloff in BV shares was accompanied by heavy trading volume. Tuesday's session — which captured the initial post-earnings reaction — saw volume of approximately 1.7 million shares, more than double the stock's average daily volume of around 660,000. Wednesday's continued decline suggests sustained selling pressure as investors digested the full implications of the report.

BrightView's decline occurred against a mixed broader market backdrop. While the stock's move was primarily company-specific, the sharp reaction underscores the market's low tolerance for earnings misses among small- and mid-cap industrial services companies — particularly those already trading near the lower end of their 52-week range. The stock breached its 50-day moving average of roughly $13.53 decisively and is now testing support near its 52-week low of $10.81.

What Comes Next for BV

Looking ahead, investors will closely monitor whether BrightView's land maintenance momentum can be sustained through the remainder of fiscal 2026 and whether the non-routine charges that plagued the third quarter prove to be truly one-time in nature. The company's next quarterly report will be critical in demonstrating whether the underlying operational improvements can finally flow through to earnings without being derailed by external headwinds.

Analyst sentiment heading into the report was mixed, with a consensus Hold rating and price targets ranging from $13 to $17. In the wake of the earnings miss, further downgrades or estimate revisions are possible. Risks include continued fuel cost volatility, potential additional insurance adjustments, and broader macroeconomic uncertainty that could impact commercial landscaping demand. For now, the burden of proof rests squarely on management to show that the turnaround is real and that profitability can catch up to operational progress.

Trending AI Robots

For investors seeking data-driven, automated trading strategies across thousands of stocks — including names like BV — Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots. These bots use algorithmic models that vary by strategy, timeframe, performance metrics, and traded symbols, and only the strongest performers under current market conditions are featured. Explore the Trending AI Robots page to discover which AI-powered strategies are navigating today's volatile market environment most effectively.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BV

Momentum Indicator for BV turns negative, indicating new downward trend

BV saw its Momentum Indicator move below the 0 level on July 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In of the 94 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BV turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

BV moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BV's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for BV moved above the 200-day moving average on July 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BV advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

BV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 200 cases where BV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.985) is normal, around the industry mean (7.685). BV's P/E Ratio (437.333) is considerably higher than the industry average of (74.493). Projected Growth (PEG Ratio) (1.182) is also within normal values, averaging (1.532). BV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (0.462) is also within normal values, averaging (8.897).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Industry description

The industry produces equipment regularly used in offices by businesses and other organizations, and could range from items like Blank sheet paper, calendars, Label and adhesive paper, paper clips, janitorial supplies, to larger /higher cost products like computers, printers, photocopiers, office furniture and so on. Many businesses in the office supply industry have been expanding into related markets like business cards, plus printing and binding of high quality, high volume business and engineering documents. Some companies in this industry also offer shipping services, including packaging and bulk mailing. Herman Miller, Inc., Steelcase Inc. and HNI Corporation.

Market Cap

The average market capitalization across the Office Equipment/Supplies Industry is 7.9B. The market cap for tickers in the group ranges from 359.74K to 89.97B. MCHSF holds the highest valuation in this group at 89.97B. The lowest valued company is JFIL at 359.74K.

High and low price notable news

The average weekly price growth across all stocks in the Office Equipment/Supplies Industry was 3%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 1%. THH experienced the highest price growth at 27%, while ULS experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Office Equipment/Supplies Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 52
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 84
Seasonality Score: -34 (-100 ... +100)
View a ticker or compare two or three
BV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company through its subsidiaries provides tree care, water management and landscape design and maintenance services

Industry OfficeEquipmentSupplies

Profile
Details
Industry
Miscellaneous Commercial Services
Address
980 Jolly Road
Phone
+1 484 567-7204
Employees
21000
Web
https://www.brightview.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.